Mostrar el registro sencillo del ítem
Aproximación a la farmacología del sulfato de magnesio desde la perspectiva obstétrica
dc.contributor.author | Rodríguez Hernández, Pablo Andrés | spa |
dc.contributor.author | Beltrán Avendaño, Mónica Andrea | spa |
dc.date.accessioned | 2020-10-27T14:19:45Z | |
dc.date.available | 2020-10-27T14:19:45Z | |
dc.date.issued | 2016-04-25 | |
dc.identifier.issn | 2382-4603 | |
dc.identifier.issn | 0123-7047 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12749/10048 | |
dc.description.abstract | Desde su primer uso en 1926 en el manejo de la eclampsia el sulfato de magnesio ha sido un medicamento utilizado y estudiado ampliamente por obstetras. Durante mucho tiempo se mantuvo escepticismo sobre sus potenciales beneficios, pero la aparición de estudios bien estructurados aportó evidencia a favor o en contra de algunos de estos. Objetivo: Realizar una revisión de la literatura acerca dela farmacología, fisiología, farmacocinética, mecanismos de acción, principales usos y regímenes de administración del sulfato de magnesio en obstetricia. Metodología: Búsqueda bibliográfica en Medline, a través de PubMed, utilizando los términos Magnesium Sulfate, Pharmacology, Obstetrics, Pre-eclampsia, Eclampsia, Neuroprotective Agents. Se adicionaron otros artículos con el fin de ampliar información en ciertos temas. Conclusiones: Las propiedades farmacológicas que expresa el sulfato de magnesio se relacionan directamente con su efecto antagónico con el calcio. Muestra efectos a nivel muscular, neuronal, cardiovascular, entre otros. Sus usos en obstetricia abarcan principalmente el manejo de la preeclampsia, prevención de la eclampsia, y prevención de la parálisis cerebral del recién nacido prematuro. El uso como agente tocolitico en el trabajo de parto prematuro aun es discutido ya que la evidencia es inconclusa. [Rodríguez-Hernández PA, Beltrán-Avendaño MA. Aproximación a la farmacología del sulfato de magnesio desde la perspectiva obstétrica. MedUNAB 2016; 19(1): 25-32]. | spa |
dc.format.mimetype | application/pdf | spa |
dc.format.mimetype | Application/vnd.openxmlformats-officedocument.wordprocessingml.document | spa |
dc.language.iso | spa | spa |
dc.publisher | Universidad Autónoma de Bucaramanga UNAB | |
dc.relation | https://revistas.unab.edu.co/index.php/medunab/article/view/2327/2221 | |
dc.relation | Https://revistas.unab.edu.co/index.php/medunab/article/view/2327/2731 | |
dc.relation.uri | https://revistas.unab.edu.co/index.php/medunab/article/view/2327 | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | |
dc.source | MedUNAB; Vol. 19 Núm. 1 (2016): Abril - Julio de 2016: Cuidado Intensivo Neonatal, Manejo del Dolor Oncológico, Revistas Publindex; 25-32 | |
dc.title | Aproximación a la farmacología del sulfato de magnesio desde la perspectiva obstétrica | |
dc.title.translated | An approach to the pharmacology of magnesium sulfate from an obstetric perspective | eng |
dc.title.translated | Abordagem farmacológica do sulfato de magnésio a partir da perspectiva obstétrica | port |
dc.publisher.faculty | Facultad Ciencias de la Salud | |
dc.publisher.program | Pregrado Medicina | |
dc.type.driver | info:eu-repo/semantics/article | |
dc.type.local | Artículo | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | |
dc.subject.keywords | Magnesium Sulfate | eng |
dc.subject.keywords | Pharmacology | eng |
dc.subject.keywords | Obstetrics | eng |
dc.subject.keywords | Neuroprotective Agents | eng |
dc.subject.keywords | Préeclâmpsia | eng |
dc.subject.keywords | Eclampsia. | eng |
dc.identifier.instname | instname:Universidad Autónoma de Bucaramanga UNAB | spa |
dc.type.hasversion | Info:eu-repo/semantics/publishedVersion | |
dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.relation.references | De Baaij JHF, Hoenderop JGJ, Bindels RJM. Magnesium in Man: Implications for Health and Disease. Physiol Rev. 2015;95(1):1–46 | |
dc.relation.references | Alfaro de la Vega G, Castelazo Ayala L, Fernández Doblado R. Assessment of current procedures in the treatment of preeclampsia. Rev Ginecol Obstet Mex. 2010;78(7):371–97 | |
dc.relation.references | Greene MF. Magnesium Sulfate for Preeclampsia. N Engl J Med. 2003;348(4):275-6 | |
dc.relation.references | KeirseMJNC.Thehistoryoftocolysis.BJOG. 2003;110(20):94–7 | |
dc.relation.references | HunterLA,GibbinsKJ.Magnesiumsulfate:past, present,andfuture.JMidwiferyWomensHealth. 2011;56(6):566–74 | |
dc.relation.references | Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial:arandomisedplacebo-controlledtrial.Lancet. 2002;359(9321):1877–90 | |
dc.relation.references | FoodandDrugAdministration.FDARecommends Against Prolonged Use of Magnesium Sulfate to Stop Pre-termLaborDuetoBoneChangesinExposed Babies.FDADrug Safety Communication. FDA; 2013 [acceso 9 de septiembre de 2015]. Disponible en : http://www.fda.gov/Drugs/DrugSafety/ucm353333.htm | |
dc.relation.references | Magnesium sulfate use in obstetrics. Committee Opinion No.652.AmericanCollegeofObstetriciansand Gynecologists. Obstet Gynecol 2016;127:e52–3 | |
dc.relation.references | Rojas-Higuera R, Londoño-Cardona JG, Arango-Gómez F.Clinical practice in looking after breastfeeding women andthenew-borninsomehospitalsinBogota, Colombia. Rev Salud Pública 2006;8(3):223–34 | |
dc.relation.references | Zuleta-Tobón JJ, Pandales-Pérez H, Sánchez S, Vélez-ÁlvarezGA,Velásquez-PenagosJA.Errorsinthe treatment of hypertensive disorders of pregnancy and their impact on maternal mortality. Int J Gynaecol Obstet Ireland; 2013;121(1):78–81 | |
dc.relation.references | Ministerio de Salud y Protección Social - Colciencias. Guías de Práctica Clínica para la prevención, detección temprana y tratamiento del embarazo, parto o puerperio. Guía No. 11-15. Bogotá, Colombia: 2013 | |
dc.relation.references | Kolte D, Vijayaraghavan K, Khera S, Sica DA, Frishman WH. Role of magnesium in cardiovascular diseases. Cardiol Rev 2014;22(4):182–92 | |
dc.relation.references | Romani,AMP. Magnesium in health and disease. Metal ions in life sciences. 2013 p.49–79 | |
dc.relation.references | HouillierP.Mechanismsandregulationofrenal magnesiumtransport.AnnuRevPhysiol2014;76: 411–30 | |
dc.relation.references | Okusanya BO, Oladapo OT, Long Q, Lumbiganon P, Carroli G, Qureshi Z, et al. Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia. BJOG2016;123(3):356–66 | |
dc.relation.references | Smith JM, Lowe RF, Fullerton J, Currie SM, Harris L, Felker-Kantor E. An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management. BMCPregnancy Childbirth 2013;13:34 | |
dc.relation.references | Magpie Trial Follow-Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years. BJOG2007;114(3):300–9 | |
dc.relation.references | Duley L, Gülmezoglu AM, Chou D. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane database SystRev2010;(9):CD002960.Doi:10.1002/ 14651858.CD002960 | |
dc.relation.references | Duley L, Henderson-Smart DJ, Walker GJ, Chou D. Magnesium sulphate versus diazepam for eclampsia. Cochrane database Syst Rev 2010;(12):CD000127. Doi: 10.1002/14651858.CD000127 | |
dc.relation.references | Duley L, Henderson-Smart DJ, Chou D. Magnesium sulphateversusphenytoinforeclampsia.Cochrane databaseSystRev2010;(10):CD000128.Doi: 10.1002/14651858.CD000128 | |
dc.relation.references | Duley L, Gülmezoglu AM, Henderson-Smart DJ, Chou D. Magnesiumsulphateandotheranticonvulsantsfor women with pre-eclampsia. Cochrane database Syst Rev2010;(11):CD000025.Doi:10.1002/ 14651858.CD000025 | |
dc.relation.references | Berhan Y, Berhan A. Should magnesium sulfate be administeredtowomenwithmildpre-eclampsia?Asystematic review of published reports on eclampsia. J Obstet Gynaecol Res 2015;41(6):831–42 | |
dc.relation.references | Duley L, Matar HE, Almerie MQ, Hall DR. Alternative magnesiumsulphateregimensforwomenwith pre‐eclampsia and eclampsia. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD007388. DOI: 10.1002/14651858.CD007388 | |
dc.relation.references | Conde-Agudelo A, Romero R, Kusanovic JP. Nifedipine in the management of preterm labor: a systematic review andmetaanalysis.AmJObstetGynecol2011;204(2):134.e1–20 | |
dc.relation.references | Tang YY, Du Y, Ni J, Ma YS, Lin XM, Zhou J. Relaxant effects of metoclopramide and magnesium sulfate on isolated pregnant myometrium: an in vitro study. Int J Obstet Anesth 2014;23(2):131–7 | |
dc.relation.references | Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, WeltonNJ.Tocolytictherapyforpretermdelivery: systematicreviewandnetworkmeta-analysis.BMJ2012;345:e6226 | |
dc.relation.references | Hösli I, Sperschneider C, Drack G, Zimmermann R, Surbek D, Irion O. Tocolysis for preterm labor: expert opinion. Arch Gynecol Obstet 2014;289(4):903–9 | |
dc.relation.references | Crowther CA, Brown J, McKinlay CJD, Middleton P. Magnesiumsulphateforpreventingpreterm birthin threatened preterm labour. Cochrane database Syst Rev 2014;(8) | |
dc.relation.references | Nijman TAJ, van Vliet EOG, Koullali B, Mol BW, Oudijk MA. Antepartum and intrapartum interventions to prevent preterm birth and its sequelae. Semin Fetal Neonatal Med 2016;21(2):121–8 | |
dc.relation.references | Navathe R, Berghella V. Tocolysis for Acute Preterm Labor: Where Have We Been, Where Are We Now, and WhereareWeGoing?AmJPerinatol 2016;33(3):229–35 | |
dc.relation.references | RethlefsenSA,RyanDD,KayRM.Classification systemsincerebralpalsy.OrthopClinNorthAm 2010;41(4):457–67 | |
dc.relation.references | Crowther CA, Middleton PF, Wilkinson D, Ashwood P, Haslam R. Magnesium sulphate at 30 to 34 weeks' gestationalage:neuroprotectiontrial(MAGENTA)--study protocol. BMCPregnancy Childbirth 2013;13:91 | |
dc.relation.references | NguyenT-MN,CrowtherCA,WilkinsonD,BainE. Magnesiumsulphateforwomenattermfor neuroprotection of the fetus. Cochrane database Syst Rev2013;(2).CD009395.Doi:10.1002/ 14651858.CD009395 | |
dc.relation.references | Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 2010;95(2):263–9 | |
dc.relation.references | MittendorfR,DambrosiaJ,PrydePG,LeeK-S, GianopoulosJG,BesingerRE,etal.Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol 2002;186(6):1111–8 | |
dc.relation.references | Crowther CA, Hiller JE, Doyle LW, Haslam RR. Effect of magnesiumsulfategivenforneuroprotectionbefore pretermbirth:arandomizedcontrolledtrial.JAMA2003;290(20):2669–76. | |
dc.relation.references | MarretS,MarpeauL,Zupan-SimunekV,EurinD, Lévêque C, Hellot M-F, et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomisedcontrolledPREMAGtrial.BJOG2007;114(3):310–8 | |
dc.contributor.cvlac | Rodríguez Hernández, Pablo Andrés [0001609223] | |
dc.contributor.orcid | Rodríguez Hernández, Pablo Andrés [0000-0003-4457-7939] | |
dc.subject.lemb | Ciencias de la vida | |
dc.subject.lemb | Medicina | |
dc.identifier.repourl | repourl:https://repository.unab.edu.co | |
dc.description.abstractenglish | Since its first use in 1926 in eclampsia´s management magnesium sulphate has been a drug used and studied extensively by obstetricians. For a long time, practitioners remained sceptical about its potential benefits but the emergence of well-structured studies provided evidence in favor and against. Objective: A review of the literature on the pharmacology, physiology, pharmacokinetics, mechanisms of action, main applications and schemes of administration of the sulfate of magnesium in obstetrics. Methodology: Search in the database MEDLINE via PubMed, using the terms: Magnesium Sulfate, pharmacology, Obstetrics, Preeclampsia, Eclampsia, Neuroprotective Agents. Other papers were added in order to expand information on some topics. Conclusions: The pharmacological properties that express the magnesium sulfate is linked directly with its effect antagonistic with the calcium. Shows effects to level muscle, neuronal, cardiovascular, among others. Its uses in obstetrics include mainly the management of preeclampsia, prevention of eclampsia, and prevention of cerebral palsy in the premature neonate. The magnesium sulphate tocolytic effects even is discussed because the evidence is inconclusive. [RodrÍguez-Hernández PA, Beltrán-Avendaño MA. An approach to the pharmacology of magnesium sulfate from an obstetric perspective. MedUNAB 2016; 19(1): 25-32] | eng |
dc.subject.proposal | Sulfato de magnesio | |
dc.subject.proposal | Farmacología | |
dc.subject.proposal | Preeclampsia | |
dc.subject.proposal | Eclampsia | |
dc.subject.proposal | Obstetricia | |
dc.subject.proposal | Fármacos neuroprotectore | |
dc.identifier.doi | 10.29375/01237047.2327 | |
dc.type.redcol | http://purl.org/redcol/resource_type/ART |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Revista MedUNAB [817]